Th e incidence of diverticulosis and diverticular disease of the colon is increasing worldwide. Although the majority of patients remains asymptomatic long-life, the prevalence of diverticular disease of the colon, including acute diverticulitis, is substantial and is becoming a signifi cant burden on National Health Systems in terms of direct and indirect costs. Focus is now being drawn on identifying the correct therapeutic approach by testing various treatments. Fiber, non-absorbable antibiotics and probiotics seem to be eff ective in treating symptomatic and uncomplicated patients, and 5-aminosalicylic acid might help prevent acute diverticulitis. Unfortunately, robust evidence on the eff ectiveness of a medical strategy to prevent acute diverticulitis recurrence is still lacking. We herein provide a concise review on the eff ectiveness and future perspectives of these treatments.
Introduction
Diverticular disease (DD) is characterized by the presence of sac-like protrusions (diverticula) which form when colonic mucosa and submucosa herniate through defects in the muscle layer of the colon wall [1] . DD is commonly found in developed countries, slightly more frequently in the USA than in Europe, and is a rare condition in Africa. However, some indication is available that the prevalence of colonic diverticulosis is increasing throughout the world, probably because of changes in lifestyle [1] . Although most people with colonic diverticulosis remain asymptomatic about 20% of patients will develop symptoms, developing so-called DD [2] , of whom 15% will ultimately develop diverticulitis [3, 4] , with or without complications (Fig. 1) .
Terminology
To aid in the discussion about DD, it is important to fi rst defi ne some key terms, including DD, diverticulosis and symptomatic uncomplicated DD (SUDD). According to currently accepted defi nitions, the following terminology is used in describing diff erent scenarios in which diverticula may be detected.
'Diverticulosis' is merely the presence of colonic diverticula; these may, or may not, be symptomatic or complicated.
'DD' is defi ned as clinically signifi cant and symptomatic diverticulosis; this may be due to true diverticulitis or to other less well-understood manifestations (e.g. visceral hypersensitivity in the absence of verifi able infl ammation). Th e overarching term DD implies that the pathologic lesion (diverticulosis) rises to the level of an illness.
'SUDD' is a subtype of DD in which there are persistent abdominal symptoms attributed to diverticula in the absence of macroscopically overt colitis or diverticulitis.
'Diverticulitis' is the macroscopic infl ammation of diverticula with related acute or chronic complications. Diverticulitis can be uncomplicated or complicated. It is uncomplicated when computed tomography (CT) shows colonic wall thickening with fat stranding, while it is complicated when CT demonstrates complicating features of abscess, peritonitis, obstruction, fi stulas or hemorrhage.
'Segmental colitis associated with diverticulosis (SCAD)' is a unique form of infl ammation that occurs in areas marked by diverticulosis. Endoscopic and histological characteristics describe it as a forerunner of infl ammatory bowel disease (IBD).
Clinical picture of DD
Clinical classifi cation of DD is still currently based on the 1999 EAES (European Association for Endoscopic Surgery) criteria, which subdivided DD as SUDD, recurrent symptomatic disease and complicated disease [5] . SUDD is characterized by nonspecifi c attacks of abdominal pain without evidence of an infl ammatory process. Th is pain is typically colicky in nature, but can be constant, and is oft en relieved by passing fl atus or having a bowel movement. Bloating and changes in bowel habits also can occur due to bacterial overgrowth, and constipation is more common than diarrhea. Fullness or tenderness in the left lower quadrant, or occasionally a tender palpable loop of the sigmoid colon, is oft en discovered on physical examination. Recurrent symptomatic disease is associated with the recurrence of the symptoms described above, and it may occur several times per year. As recently underlined, these symptoms may resemble irritable bowel syndrome (IBS) [6] . Moreover, it has been recently described that IBS occurs 4.7-fold more likely in patients aft er an episode of acute diverticulitis than controls. Several factors seem to explain persistence of symptoms in those patients, such as signifi cant attenuation in serotonin-transporter expression [7] , increased neuropeptide expression in colonic mucosa [8] , and persistence of low-grade infl ammation [9] . Hence, in this way, it seems to be appropriate to speak of IBS-like symptoms rather than IBS in those patients. On the contrary, it may be quite diffi cult to diff erentiate SUDD from IBS. Clinical and laboratory parameters may be useful. Cuomo et al recently found that only a minority of DD patients (10%) fulfi lled the criteria for IBS diagnosis and that abdominal pain >24 h was more prevalent in SUDD than in IBS patients (P<0.01). It was also demonstrated that, compared with IBS, DD patients had more episodes of pain lasting 24 h requiring medical attention (P<0.01) [10] . More recently, we investigated 72 patients suff ering from abdominal pain with diverticula identifi ed on colonoscopy, of whom 42 were classifi ed as having SUDD (abdominal pain for at least 24 consecutive h in the left lower abdomen), and 30 were classifi ed as having IBSlike symptoms fulfi lling Rome III criteria. All patients underwent fecal calprotectin (FC) determination and it was found that FC levels were elevated in 64.3% of SUDD patients and in none of the patients in the IBS-like group (P<0.0001). Moreover, the severity of the abdominal pain and the FC score correlated signifi cantly in SUDD patients (P=0.0015) [11] . FC is particularly useful in this setting, because raised FC may be detected in SUDD, acute diverticulitis and SCAD but not in IBS. Hence, the characteristic of abdominal pain (left lower quadrant pain lasting >24 h), and the detection of raised FC are very useful in achieving a correct diff erential diagnosis between IBS and DD in a patient with diverticulosis of the colon [12] .
Th e development of infl ammation in these diverticula results in acute diverticulitis. It has been suggested that in the same way, obstruction by fecal material causes appendicitis, that fecal matter becomes trapped in the diverticula and as a result, low-grade infl ammation develops due to abrasion of the mucosa, allowing access of fecal microbiota to the lamina propria, leading to acute infl ammation of the mucosa, which usually begins at the apex of the sac [13, 14] . Th is can be associated with acute infl ammation of the mesenteric and pericolic fat with the formation of a diverticular abscess. Another postulated mechanism for the development of acute diverticulitis is a micro-perforation at the fundus of the diverticulum leading to infl ammation [15] .
Acute diverticulitis of the colon represents a signifi cant burden for National Health Systems so far, in terms of direct and indirect costs [16] . Moreover, this disease seems to relapse more frequently than previously thought. In fact, a recent study found that overall disease relapse during a 10-year follow up is up to 40% [17] . Until recently the guideline was based on the assumption that recurrent episodes (two or more) of diverticulitis will lead to complicated diverticulitis and higher mortality [18] . However, multiple episodes of diverticulitis do not seem to be associated with increased mortality or an increased risk of complicated diverticulitis. Th e overall mortality rate for patients with a prior history of diverticulitis was 2.5%, comparing favorably with a mortality rate of 10% for patients with a fi rst presentation of complicated diverticulitis [19] . In addition, 78% of patients with perforated diverticulitis had no prior history of diverticulitis [20] . Elective sigmoid resection for diverticulitis is associated with risks of mortality and colostomy as high as 2.3% and 14.2% respectively [21] [22] [23] . Furthermore, the risk of recurrent diverticulitis is not eliminated aft er sigmoid resection, with recurrence rates between 2.6% and 10.4%. In this way, the American Society of Colon and Rectal Surgeons revised their recommendations in 2006 and recommended an individualized approach to patients aft er an attack of acute diverticulitis [24] .
Medical treatment of diverticular disease

SUDD
Fiber
According to current WGO Guidelines, many clinicians advise spasmolytics and a high-fi ber diet or fi ber supplementation, which still represent the fi rst-line treatment for SUDD [25] . However, a recent systematic review found that high-quality evidence for a high-fi ber diet in the treatment of DD is lacking, and most recommendations are based on inconsistent level 2 and mostly level 3 evidence [26] . Only three randomized, placebo-controlled trials of adequate quality were identifi ed, giving contradictory results [27, 28] . Th is systematic review did not found a signifi cant diff erence between soluble versus insoluble fi ber. Only one randomized, placebo-controlled study compared insoluble (bran, 6.99 g/day) with soluble fi ber (ispaghula 9.04 g/day) and placebo (2.34 g/day), taken for 16 weeks. Th ere were no signifi cant diff erences in pain, lower bowel symptoms or total symptom scores taking crisp bread, ispaghula drink and placebo. Surprisingly, Peery et al recently found that high intake of soluble fi ber had a higher risk of diverticulosis occurrence (P=0.038) [29] . Nevertheless, a high-fi ber diet is still recommended. Adequate quality controlled studies in using fi ber in such patients are reported in Table 1 .
Antibiotics
Since 1992, the use of rifaximin has been investigated in the treatment of SUDD. Th is is a poorly absorbable antibiotic with a broad spectrum of action, including action against Grampositive and -negative bacteria, aerobes and anaerobes [30] . It has been successfully used in recent years in the treatment of SUDD, and also seems to be eff ective in maintaining SUDD remission. A recent meta-analysis examined four prospective randomized trials (only one conducted in double-blind placebo-controlled fashion) including 1660 patients. Th e pooled rate of diff erence for symptom relief was 29.0% in favor of rifaximin (rifaximin vs. control; 95% CI 24.5-33.6; P<0.0001) with a clinically signifi cant Number Needed to Treat (NNT=3) [31] . Controlled studies of rifaximin in such patients are reported in Table 2 .
Mesalazine
Controlling infl ammation with mesalazine is another option for the treatment of SUDD. Although this drug has been eff ectively used for many years in the treatment of IBD, the mechanisms of action are not yet well understood. Mesalazine acts in the gastrointestinal epithelium through N-Ac-5-ASA, the active metabolite of 5-ASA (mesalazine), but the molecular mechanisms of its action are not clear. It is thought that mesalazine inhibits some key factors of the infl ammatory cascade (cyclo-oxygenase, thromboxane-synthetase and PAFsynthetase); inhibits the production of interleukin-1 and free radicals; and has intrinsic antioxidant activity [32] . In the light of new data on the role of infl ammation in the pathogenesis of SUDD, it was inevitable that researchers would attempt to apply mesalazine based on this indication. Although limited by the open-label design, the favorable eff ect of mesalazine on SUDD has been demonstrated by several open-label studies [33, 34] . Th ree double-blind, placebo-controlled studies have also recently assessed the role of mesalazine in treating those patients. Th e fi rst trial investigated the effi cacy and safety of mesalazine granules 3 g/day vs. placebo in patients with lower abdominal pain as a symptom of SUDD. Change in lower abdominal pain to week 4 (baseline defi ned using pain score from 7 days pre-treatment) was signifi cantly lower in the mesalazine group (P=0.05) in the per-protocol (PP) but not on intention-to-treat (P=0.374) population. Post hoc adjustment for confounding factors resulted in P=0.005 (PP). Safety was comparable [35] . Th e second trial assessed the eff ectiveness of mesalazine, with or without probiotic, vs. placebo in maintaining remission in SUDD patients. Four groups were randomly enrolled: Group M (active mesalazine 1.6 g/day plus Lactobacillus casei (L. casei) subsp. DG placebo), Group L (active L. casei subsp. DG 24 billion/day plus mesalazine placebo), Group LM (active L. casei subsp. DG 24 billion/day plus active mesalazine), Group P (L. casei subsp. DG placebo plus mesalazine placebo). SUDD recurred in none (0%) of the patients in group LM, in 7 (13.7%) patients in group M, in 8 (14.5%) patients in group L, and in 23 (46.0%) patients in group P (LM group vs. M group, P=0.015; LM group vs. L group, P=0.011; LM group vs. P group, P=0.000; M group vs. P group, P=0.0001; L group vs. P group, P=0.0001). No adverse events were recorded during the study [36] . Another double-blind, placebo-controlled trial not yet published assessed the effi cacy of mesalazine in controlling abdominal pain in SUDD as a secondary endpoint. Patients with SUDD underwent fl exible sigmoidoscopy and biopsies at baseline and aft er 12-week treatment, completing diaries of pain and bowel habits. Patients were randomized to receive mesalazine 3 g/day (group M) or placebo (group P) for 12 weeks with follow-up visits at 2 and 4 weeks. In Group M but not in Group P there was a signifi cant reduction in the duration of abdominal pain (P=0.0413) [37] . Controlled studies of mesalazine use in such patients are reported in Table 3 .
Probiotics
Using probiotics is a third choice for the treatment of SUDD. Probiotics are living micro-organisms, which can exert host health benefi ts beyond those of inherited basic nutrition [38] . Th e pathophysiological actions of probiotics include pathogen adherence inhibition, increasing IgA secretion in Peyer's patches, increasing immune system activity inhibiting the release of anti-infl ammatory cytokines and inhibiting pro-infl ammatory cytokines. However, some bacteria may provide specifi c health benefi ts when consumed as a food component or in the form of specifi c preparations of viable micro-organisms, without the risk of antibiotic resistance. Recent studies investigated the eff ect of probiotics on the course of SUDD. All found diff erent probiotic strains eff ective in treating SUDD patients [39] [40] [41] but the open-label designs limited the usefulness of these results. Finally, in the double-blind, placebo-controlled trial, already mentioned, the combinations of mesalazine with L. casei subsp. DG (group LM) or L. casei subsp. DG alone (group L) were signifi cantly better than placebo in preventing SUDD recurrence (LM group vs. P group, P=0.000; L group vs. P group, P=0.000) [36] . Controlled studies of probiotics in such patients are reported in Table 4 .
Prevention of acute diverticulitis
Primary prevention of acute diverticulitis is a very important topic. Acute diverticulitis, defi ned as acute infl ammation of a colonic diverticulum, is a common emergency presentation managed by both surgeons and physicians. Factors predisposing to the development of acute diverticulitis include obesity, smoking, lack of physical activity and medication use such as non-steroidal anti-infl ammatory drugs.
Th ere have been advances in the medical treatments off ered to patients in recent years. Patients with uncomplicated diverticulitis are generally treated as outpatients with a clear liquid diet and antibiotics [42] . In outpatients, broad-spectrum antibiotics are usually given for 7-10 days. If opioid analgesics are required for pain control, meperidine is the preferred option since morphine causes colonic spasm and may accentuate colonic hyper-segmentation.
Outpatient treatment is eff ective in most cases, and less than 10% of patients are readmitted at the emergency room for diverticulitis within 60 days of the initial evaluation. Hospitalization with intravenous antibiotic treatment is usually recommended by current guidelines if the patient: is unable to take oral therapy; is aff ected by severe comorbidity; fails to improve with outpatient therapy; or is aff ected by complicated diverticulitis. Clinical improvement in patients aff ected by acute diverticulitis is generally observed within 3-4 days. If patients are hospitalized, a 7-10 day course of oral antibiotics is usually given following discharge. However, results of studies investigating such prevention are oft en confl icting.
Fiber
Data on the role of fi ber in primary prevention of diverticulitis are particularly confl icting [43] [44] [45] . Patients with a history of diverticulosis or DD commonly seek dietary and lifestyle recommendations to reduce their risk of occurrence/recurrence of the disease and/or complications. Th e traditional recommendation has been to consume a highfi ber diet. Using data from a single case-control study that included 56 participants, it is estimated that a high-fi ber diet might reduce the number of complications (by 52 cases per 1000 patients treated) and the need for surgery (by 100 cases per 1000 patients treated [43] ). Based on a prospective cohort study that examined the association of dietary fi ber intake and risk of incident hospitalization for DD, it is estimated that a high-fi ber diet may reduce the risk of acute diverticulitis by 59 cases per 1000 patients [45] . We rated the quality of this evidence as very low based on substantial diff erences between our target population (those with a history of diverticulitis) and those in the cohort study (those without a history of diverticulitis). Only three randomized trials analyzed the role of fi ber in preventing diverticulitis occurrence in those patients. Unfortunately, their sample size was far too small to demonstrate a signifi cant eff ect of high-fi ber supplementation on the prevention of acute uncomplicated diverticulitis or other complications of DD (e.g. abscess, perforation, stenosis, fi stula or bleeding).
Rifaximin
Data from three open randomized trials (comprising a total of 1492 patients) and four comparing rifaximin plus glucomannan or fi ber supplementation vs. glucomannan or fi ber alone, reported that rifaximin led to a slight benefi t in preventing acute diverticulitis, but only the largest study showed signifi cant results. Cumulative data from placebocontrolled and unblinded trials showed that the rate of acute diverticulitis was signifi cantly less frequent in patients treated with rifaximin plus fi ber supplementation than with fi ber alone (11/970 (1.1%) vs. 20/690 (2.9%; P=0.012) [46] [47] [48] [49] . According to these results, the number needed to be treated to prevent an attack of acute diverticulitis in 1 year with the rifaximin plus fi ber supplementation regimen reached is 57 (NNT: 57). Only one double-blind, placebo-controlled trial assessed the prevention of acute diverticulitis as a secondary endpoint. Th is was a 1-year follow-up trial in which all patients received glucomannan (2 g/day); one arm received rifaximin (400 mg b.i.d. for 7 days each month), and the other arm received a placebo. Rifaximin failed to show superiority over placebo in preventing acute diverticulitis, which occurred in 2.4% of patients in both study arms [48] .
Mesalazine
Data from fi ve randomized open trials (comprising more than 400 patients) comparing mesalazine alone or in combination with probiotics, and probiotics alone in 
Figure 2
Management of symptomatic uncomplicated diverticular disease preventing acute diverticulitis, did not show any signifi cant diff erence. However, there were only seven episodes of acute diverticulitis per year (yearly incidence rate of 2%) [33, 34, [50] [51] [52] . More recently, a double-blind, doubledummy placebo-controlled trial assessed the prevention of acute diverticulitis occurrence as secondary endpoint. Th is was a 1-year follow-up trial in which patients received mesalazine (1.6 g/day for 10 days/month), a probiotic (L. casei subsp. DG 24 billion/day for 10 days/month), mesalazine plus probiotic, or placebo. Th is study found mesalazine signifi cantly better than placebo in preventing acute diverticulitis, which occurred in none of the patients in the mesalazine group, in 1.78%, and in 12% of patients in the probiotic and placebo study arms respectively [36] . Fig. 2 shows advice on how to manage such patients based on the above-mentioned data.
Diverticular infl ammation and complications assessment (DICA) classifi cation: Is the solution around the corner?
Several radiological and clinical approaches are currently available to classify DD. Surprisingly, an endoscopic classifi cation of the disease is still lacking, considering the high number of colonoscopies performed in our centers and the percentage of signs of diverticular infl ammation detected by colonoscopy in everyday practice [53, 54] . Selecting patients according to the colonic characteristics may be an option to increase therapeutic effi cacy. To this end, an endoscopic classifi cation of DD has been recently developed and validated [55] . Th is classifi cation, called DICA, assesses four main items (diverticulosis extension, number of diverticula in each district, presence of infl ammation, and presence of complications) and some sub-items, and scores the disease in three grades: DICA 1, DICA 2 and DICA 3 ( Table 5) . Preliminary retrospective data found that this classifi cation is able to predict the outcome of the disease according to the severity of the score. In other words, simple and/or asymptomatic diverticulosis does not appear to need any maintenance treatment to prevent occurrence of complications, while a colon with signs of recurrent infl ammatory attack may be unresponsive to maintenance treatment to prevent recurrence of complications. On the contrary, DICA 2 seems to be very responsive to scheduled treatment. In other words, symptomatic diverticulosis with/without signs of infl ammation responds very well to maintenance treatment for the prevention of occurrence/recurrence of complications. If further, prospective studies confi rm these results, then we will have a clear subgroup of patients that can be expected to benefi t from scheduled maintaining treatment.
Concluding remarks
DD is a multifactorial disease in which optimal patient stratifi cation according to the severity of the disease may guarantee therapeutic success. DICA classifi cation is a new and practical instrument that can be used by clinicians for the objective description of the colon harboring diverticula. Th e simplicity of this classifi cation, its excellent reproducibility and its correlation with biochemical and clinical disease markers make it very attractive in clinical practice. Of course, further studies are needed to validate this classifi cation and to assess its reproducibility in clinical trials, as well as to assess whether its use may impact upon the natural history of DD.
